FastWave Medical has announced the issuance of its sixth utility patent by the US Patent and Trademark Office (USPTO), the fourth patent the company has been granted this year.
FastWave Medical’s intravascular lithotripsy (IVL) systems are designed to address calcified arteries. Vessels burdened with calcium pose significant challenges in treating vascular blockages safely and efficiently.
FastWave aims to empower physicians with breakthrough IVL devices to navigate complex arterial disease more effectively, reduce complications, and enhance overall patient outcomes.
“IVL has become a go-to tool for calcium modification and vessel preparation in large part due to its ease of use. I’m particularly excited about the potential of FastWave’s IVL devices in critical areas like catheter deliverability and energy durability. These types of improvements will lead to a more reliable first-line approach to tackle challenging cases,” said Raj Dave, president of Cardiovascular Experts of Pennsylvania (Camp Hill, USA).
With physicians increasingly relying on IVL for complex cases of calcific artery disease, innovations like FastWave’s are crucial in improving outcomes and making a tangible difference among at-risk patient populations with peripheral and coronary blockages.
“Our sixth utility patent is another step forward in our mission of providing physicians with leading-edge IVL technology,” said Scott Nelson, co-founder and CEO of FastWave Medical. “Our approach to development is rooted in key feedback from interventionalists across the world and I’m really proud of the progress our stellar engineering team has made in such a short time.”
